NCT05460325 - A Study of Lanadelumab (SHP643) in Chinese Participants With Hereditary Angioedema (HAE) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 22, 2022

Primary Completion Date

November 28, 2023

Study Completion Date

November 28, 2023

Conditions

Hereditary Angioedema (HAE)

Interventions

DRUG

Lanadelumab

Lanadelumab subcutaneous injection

Trial Locations (4)

Peking Union Medical College Hospital, Beijing

Yantai Yuhuangding Hospital, Yantai

Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan

The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou